Literature DB >> 20696792

Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.

Luca Manetti1, Fausto Bogazzi, Clara Giovannetti, Valentina Raffaelli, Maura Genovesi, Giovanni Pellegrini, Lucia Ruocco, Aldo Iannelli, Enio Martino.   

Abstract

OBJECTIVES: To evaluate whether patients with Cushing's syndrome (CS) had i) changes in coagulative and fibrinolytic parameters associated with CS activity and ii) higher prevalence of venous thromboembolic events (VTE).
DESIGN: Prospective study conducted on patients with CS evaluated at diagnosis and 12 months after surgery. PATIENTS AND METHODS: Forty patients with active CS (36 with Cushing's disease (CD) and 4 with an adrenal adenoma) were evaluated. Forty normal subjects and 70 patients with non-ACTH-secreting pituitary adenomas served as controls. All patients and controls underwent an assessment of coagulation and fibrinolysis indexes before and after surgery.
RESULTS: CS patients at baseline had a hypercoagulative phenotype when compared with normal subjects (activated partial thromboplastin time (aPTT), fibrinogen, D-Dimer, von Willebrand factor (VWF), plasminogen activator inhibitor 1 (PAI-1 or SERPINE1), antithrombin III (ATIII or SERPINC1), P<0.0001, α(2) antiplasmin, P=0.0004, thrombin-antithrombin complex (TAT), P=0.01, factor IX (F9), P=0.03). Patients with still active disease after surgery had higher coagulative parameters than those in remission (VWF (P<0.0001), PAI-1 (P=0.004), TAT (P=0.0001), ATIII (P=0.0002) and α(2) antiplasmin (or SERPINF2; P=0.006)), whereas aPTT levels (P=0.007) were significantly reduced. VTE occurred in three patients with CD (7.5%): one had a pulmonary embolism and two patients had a deep venous thrombosis; no patients submitted to transsphenoidal surgery for non-Cushing's pituitary adenoma had VTE (P=0.04).
CONCLUSIONS: Patients with CS have a procoagulative phenotype due to cortisol-associated changes in haemostatic and fibrinolytic markers, leading to increased incidence of VTE. Thromboprophylaxis seems to be appropriated in patients with active disease, particularly in the postoperative period.

Entities:  

Mesh:

Year:  2010        PMID: 20696792     DOI: 10.1530/EJE-10-0583

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  27 in total

1.  Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?

Authors:  Mattia Barbot; Viviana Daidone; Marialuisa Zilio; Nora Albiger; Linda Mazzai; Maria Teresa Sartori; Anna Chiara Frigo; Massimo Scanarini; Luca Denaro; Marco Boscaro; Sandra Casonato; Filippo Ceccato; Carla Scaroni
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  Determinants of the thrombogenic potential of multiwalled carbon nanotubes.

Authors:  Andrew R Burke; Ravi N Singh; David L Carroll; John D Owen; Nancy D Kock; Ralph D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

3.  Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

Authors:  Mattia Barbot; Valentina Guarnotta; Marialuisa Zilio; Filippo Ceccato; Alessandro Ciresi; Andrea Daniele; Giuseppe Pizzolanti; Elena Campello; Anna Chiara Frigo; Carla Giordano; Carla Scaroni
Journal:  Endocrine       Date:  2018-07-06       Impact factor: 3.633

4.  Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Authors:  Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-02-22       Impact factor: 2.936

Review 5.  Clinical consequences of Cushing's syndrome.

Authors:  Elena Valassi; Iris Crespo; Alicia Santos; Susan M Webb
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

6.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

7.  Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?

Authors:  S Koutroumpi; L Spiezia; N Albiger; M Barbot; M Bon; S Maggiolo; S Gavasso; P Simioni; A Frigo; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

8.  Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report.

Authors:  S Gazioglu; D Solmaz; C Boz
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

Review 9.  Cushing's Disease - Quality of Life, Recurrence and Long-term Morbidity.

Authors:  Isabel Huguet; Georgia Ntali; Ashley Grossman; Niki Karavitaki
Journal:  Eur Endocrinol       Date:  2015-04-11

10.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.